In Vitro and in Vivo Evaluation of a Technetium-99m-Labeled 2-Nitroimidazole (BMS181321) as a Marker of Tumor Hypoxia

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 1023-1031

  Ballinger, James R ^a   Kee, Judy Wan Min ^b   Rauth, Andrew M ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

Hypoxia; Nitroimidazole; Technetium 99m; Tumors

Indexed keywords

DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN; TECHNETIUM; TECHNETIUM COMPLEX;

ANIMAL; ARTICLE; C3H MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL HYPOXIA; CHO CELL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HAMSTER; IN VITRO STUDY; MALE; METABOLISM; MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; CELL HYPOXIA; CHO CELLS; CRICETINAE; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; ORGANOTECHNETIUM COMPOUNDS; OXYGEN; TECHNETIUM; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0030162585     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. Concentration of oxygen dissolved in tissues at time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-648.
2. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313-341.
3. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engt J Med 1979:301:1429-1432.
4. 18F]-fluoromisonidazole. Int J Radiat Oncol Biol Phys 1991;22:199-212.
5. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 1992;33:2202-2208.
6. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-dcoxy-beta-D-arabinofuranosyl)-2-nitro-imidazole (lodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991;32:1764-1770.
7. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992;65:90-95.
8. Groshar D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993;34:885-888.
9. Biskupiak JE, Grierson JR, Rasey JS, Martin GV, Krohn KA. Synthesis of an (iodovinyl)misonidazole derivative for hypoxia imaging. J Med Chem 1991;34:2165-2168.
10. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med 1993;34:918-924.
11. Linder KE, Cyr J, Chan YW, et al. Chemistry of a Tc-PnAO-nitroimidazole complex that localizes in hypoxic tissue [Abstract]. J Nucl Med 1992;33:919.
12. DiRocco RJ, Bauer A, Kuczynski BL, et al. Imaging regional hypoxia with a new technetium-labeled imaging agent in rabbit myocardium after occlusion of the left anterior descending coronary artery [Abstract]. J Nucl Med 1992;33:865.
13. Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnAO-1-(2-nitroimidazole)) [BMS181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17.
14. DiRocco RJ, Kuczynski BL, Pirro JP, et al. Imaging ischemic tissue at risk of infarction during stroke. J Cereb Blond Flow Melab 1993;13:755-762.
15. 99m]Tc-labeled nitroheterocycle capable of identification of hypoxia in heart. Biochem Biophys Res Commun 1993; 193:1239-1246.
16. Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker. tcchnetium-99m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med 1994;35:1371-1376.
17. 31P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1992;22:473-476.
18. Wood PJ, Stratford IJ, Adams GE, Szabo C, Thiemermann C, Vane JR. Modification of energy metabolism and radiation response of a murine tumor by changes in nitric oxide availability. Biachem Biophys Res Commun 1993;192:505-510.
19. 99mTc-DTPA in radiopharmaceutical kits [Abstract]. J Nucl Med 1994;35:138P.
20. Taylor YC, Rauth AM. Oxygen tension, cellular respiration and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res 1982;91:104-123.
21. Ballinger JR, Cowan DSM, Boxen I, Zhang ZM, Rauth AM. Effect of hypoxia on the accumulation of technelium-99m-glucarate and technetium-99m-gluconate by Chinese hamster ovary cells in vitro. J Nucl Med 1993;34:242-245.
22. Marshall RS, Koch CJ, Rauth AM. Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system. Radiat Res 1986;108:91-101.
23. Whillans DW, Rauth AM. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res 1980;84:97-114.
24. Bristow RG, Hardy PA, Hill RP. Comparison between in vitro radiosensitivity and in vivo response of murine tumor cell lines. I. Parameters of in vitro radiosensitivity and endogenous cellular glutathione levels. Int J Radiat Oncol Biol Phys 1990;18:133-145.
25. Taylor YC, Rauth AM. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res 1978;38:2745-2752.
26. Koch CJ, Giandomenico AR, Iyengar CW. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers. Biochem Pharmacol 1993;46:1029-1036.
27. Marshall RS, Rauth AM. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analog, in Chinese hamster ovary cells. Cancer Res 1988;48:5655-5659.
28. Rauth AM, Marshall RS, Kuehl BL. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev 1993;12:153-164.
29. Chan YW, Linder KE, Jayatilak PG, et al. In-vitro studies of the hypoxic retention of a novel technetium-99m labeled nitroimidazole in rat heart [Abstract]. J Nucl Med 1994;35:18P-19P.
30. McClelland RA, Panicucei R, Rauth AM. Products of the reduction of 2-nitroimidazoles. J Am Chem Soc 1987;109:4308.
31. Chapman JD, Ball K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1993;43:1523-1528.
32. 3H]misonidazole binding and paired survival assay. Radiat Res 1996;145:491-500.
33. Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987;28:68-75.
34. Rumsey WL, Patel B, Linder KE. Effect of graded hypoxia on retention of technetium-99m-nitroheterocycle in perfused rat heart. J Nucl Med 1995;36:632-636.